Ann: Travelan to progress to Phase 3 Clinical Trials in the US, page-91

It's a worthwhile consideration. This is a hot potato and has a history of such price actions. You risk missing out on further gains (in 2020 this briefly went into the 80c-90c range on speculative fervor) but I think the end result will be the same. On fundamentals, you just have to compare the findings of the 3 dosage daily study, to the current 1 a day dosage study. The links to that "Otto" study are even conveniently presented in the announcement. Look at how many got sick after taking colostrum then, versus now. Draw your own conclusions. GL.